Recombinant Antibody Network

重组抗体网络

基本信息

批准号：
8545885
负责人：
ANTHONY A KOSSIAKOFF
金额：
$ 180.73万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-26 至 2016-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8545885
关键词：
Affinity Animals Antibodies Antibody Affinity Antibody Formation Antigens Architecture Area Arizona Back Binding Biological Assay Biological Sciences Biology Biomedical Research Budgets Cell Line Cells Characteristics Chicago Data Feedback Generations Goals Human Hybridomas Immunization Immunofluorescence Immunologic Immunoglobulin G Immunoprecipitation Individual Intellectual Property International Internet Length Link Modeling Monoclonal Antibodies Output Performance Phage Display Plasmids Procedures Process Production Protein Binding Proteins Proteome Protocols documentation Reagent Recombinant Antibody Recombinant Proteins Research Research Personnel San Francisco Speed Technology Time Universities Validation Vendor Western Blotting Work antibody engineering base chromatin immunoprecipitation cost design expression vector feeding flexibility high throughput technology improved member open source operation process optimization protein function repository restraint success transcription factor

项目摘要

DESCRIPTION (provided by applicant): The RAN is a collaborative international tri-center partnership having the unified goal of generating customized affinity capture reagents to all the human transcription factors. The five-year goal of the RAN is to establish a robust and efficient pipeline that will allow for reliable selection of high quality recombinant antibody (rAB) reagents that are superior in quality and are much cheaper and quicker to produce than those generated by hybridism technology. Generation of a renewable, validated and standardized set of antibody reagents would enable unprecedented studies of protein function and would accelerate research in all fields related to life sciences. The RAN will be directed by a leading group of antibody engineers who have an established track record of working collaboratively together for decades. Each of the centers will have a high throughput technology platform with the proven capabilities to generate high quality recombinant antibodies (rABs). The distributive model of the RAN centers provides for distributing individual Tasks among centers to be worked on in an Independent manner, but ultimately tied together by input/output conduits that feed back into all operations in the network. The core pieces of the pipeline have been rigorously validated and have exceptional capacity as demonstrated in our Preliminary Results. We will have established high-throughput validation procedures that assess antibody performance from affinity to activity in cells and ChIP analysis. The RAN's high throughput (HTP) pipelines will generate rABs in multiple formats using established and optimized automated phage display to 1500 human TFs provided by our collaborators and others. We will use HTP validation procedures to produce at least two rABs per transcription factor for high performance in: binding (KD <50 nM), Western blotting, immunoprecipitation (IP), immunofluorescence (IF) and chromatin immunoprecipitation (ChIP). We will distribute sequence information and open source reagents in multiple formats through multiple distribution channels. The impact of this project will be to accelerate the rate and reduce the cost of research in transcription factors (TFs) specifically and the proteome in general.

描述（由申请人提供）：RAN 是一个国际三中心合作伙伴关系，其统一目标是为所有人类转录因子生成定制的亲和捕获试剂。 RAN 的五年目标是建立一个强大而高效的管道，以便可靠地选择高质量的重组抗体 (rAB) 试剂与混合技术生产的产品相比，它们的质量更高，生产成本更低，生产速度更快。一套可再生、经过验证和标准化的抗体试剂的产生将使对蛋白质功能的前所未有的研究成为可能，并将加速与生命科学相关的所有领域的研究。 RAN 将由领先的抗体工程师团队领导，他们拥有数十年合作的良好记录。每个中心都将拥有高通量技术平台，具有生产高质量重组抗体 (rAB) 的成熟能力。 RAN 中心的分布式模型提供了在各个中心之间分配各个任务，以独立的方式进行工作，但最终通过反馈到网络中所有操作的输入/输出管道连接在一起。该管道的核心部分已经过严格验证，并具有我们的初步结果所证明的卓越能力。我们将建立高通量验证程序，评估从亲和力到细胞活性和 ChIP 分析的抗体性能。 RAN 的高通量 (HTP) 管道将使用我们的合作者和其他人提供的已建立和优化的自动噬菌体展示对 1500 个人类 TF 生成多种格式的 rAB。我们将使用 HTP 验证程序为每个转录因子生成至少两个 rAB，以实现以下方面的高性能：结合 (KD <50 nM)、蛋白质印迹、免疫沉淀 (IP)、免疫荧光 (IF) 和染色质免疫沉淀 (ChIP)。我们将通过多种分发渠道以多种格式分发序列信息和开源试剂。该项目的影响将是加快转录因子（TF）和蛋白质组研究的速度并降低研究成本。